Leukemia SWOG 1117

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Connect With Us

Subscribe to Our Newsletters

Get the latest healthcare news directly in your inbox.

Hartford HealthCare Offices

One State Street, Suite 19, Hartford, CT 06103 • Contact Us

Donations to Hartford HealthCare are managed by the Hartford Hospital Department of Philanthropy, a Connecticut tax-exempt organization under section 501(c)(3) of the IRS code (E.I.N. 06-0646668). For more information, click here.